Alzheon Initiates Phase 2 and 3 Open-Label Extensions for Alzheimer Agent ALZ-801.

Published Date: 05 May 2024

After completing 156 weeks of treatment, participants in the phase 2 biomarker trial were offered the opportunity to enrol in a 52-week extension to monitor various outcomes such as safety, evaluations of plasma biomarkers, and cognitive effects.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belgian Algorithm Reshapes Endometrial Cancer Care

2.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

3.

Nuclear missile workers are contracting cancer: They blame the bases

4.

On all CAR-T products, the FDA is calling for a new boxed warning.

5.

ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot